Found: 23
Select item for more details and to access through your institution.
Tumor Hypoxia and the Future of Cancer Management.
- Published in:
- Oncology (08909091), 2007, v. 21, n. 3, p. 377
- By:
- Publication type:
- Article
Volume dependence in hypoxia‐targeted dose escalation.
- Published in:
- Medical Physics, 2018, v. 45, n. 11, p. 5325, doi. 10.1002/mp.13176
- By:
- Publication type:
- Article
Theoretical effectiveness of cell survival in fractionated radiotherapy with hypoxia-targeted dose escalation.
- Published in:
- Medical Physics, 2017, v. 44, n. 5, p. 1975, doi. 10.1002/mp.12177
- By:
- Publication type:
- Article
PET-CT in head and neck cancer.
- Published in:
- Applied Radiology, 2010, v. 39, n. 4, p. 20, doi. 10.37549/ar1746
- By:
- Publication type:
- Article
Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography.
- Published in:
- Cancer (0008543X), 2002, v. 94, n. 12, p. 3277, doi. 10.1002/cncr.10599
- By:
- Publication type:
- Article
Biokinetics of Radiolabeled Monoclonal Antibody BC8: Differences in Biodistribution and Dosimetry among Hematologic Malignancies.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 12, p. 1, doi. 10.2967/jnumed.119.234443
- By:
- Publication type:
- Article
Biokinetics of Radiolabeled Monoclonal Antibody BC8: Differences in Biodistribution and Dosimetry among Hematologic Malignancies.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 11, p. 1, doi. 10.2967/jnumed.119.234443
- By:
- Publication type:
- Article
Biokinetics of Radiolabeled Monoclonal Antibody BC8: Differences in Biodistribution and Dosimetry among Hematologic Malignancies.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 10, p. 1, doi. 10.2967/jnumed.119.234443
- By:
- Publication type:
- Article
Biokinetics of Radiolabeled Monoclonal Antibody BC8: Differences in Biodistribution and Dosimetry among Hematologic Malignancies.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 9, p. 1, doi. 10.2967/jnumed.119.234443
- By:
- Publication type:
- Article
Biokinetics of Radiolabeled Monoclonal Antibody BC8: Differences in Biodistribution and Dosimetry among Hematologic Malignancies.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 8, p. 1, doi. 10.2967/jnumed.119.234443
- By:
- Publication type:
- Article
Biokinetics of Radiolabeled Monoclonal Antibody BC8: Differences in Biodistribution and Dosimetry among Hematologic Malignancies.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 7, p. 1, doi. 10.2967/jnumed.119.234443
- By:
- Publication type:
- Article
Biokinetics of Radiolabeled Monoclonal Antibody BC8: Differences in Biodistribution and Dosimetry among Hematologic Malignancies.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 6, p. 1, doi. 10.2967/jnumed.119.234443
- By:
- Publication type:
- Article
Biokinetics of Radiolabeled Monoclonal Antibody BC8: Differences in Biodistribution and Dosimetry among Hematologic Malignancies.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 5, p. 1, doi. 10.2967/jnumed.119.234443
- By:
- Publication type:
- Article
Biokinetics of Radiolabeled Monoclonal Antibody BC8: Differences in Biodistribution and Dosimetry among Hematologic Malignancies.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 4, p. 1, doi. 10.2967/jnumed.119.234443
- By:
- Publication type:
- Article
<sup>18</sup>F-Fluoromisonidazole Quantification of Hypoxia in Human Cancer Patients Using Image-Derived Blood Surrogate Tissue Reference Regions.
- Published in:
- Journal of Nuclear Medicine, 2015, v. 56, n. 8, p. 1223, doi. 10.2967/jnumed.115.158717
- By:
- Publication type:
- Article
From the SNM Nuclear Oncology Council.
- Published in:
- Journal of Nuclear Medicine, 2009, v. 50, n. 2, p. 28N
- By:
- Publication type:
- Article
A phase II trial evaluating the efficacy of high‐dose Radioiodinated Tositumomab (Anti‐CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high‐risk relapsed or refractory non‐hodgkin lymphoma
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 7, p. 775, doi. 10.1002/ajh.25818
- By:
- Publication type:
- Article
Myeloablative <sup>131</sup>I-Tositumomab Radioimmunotherapy in Treating Non-Hodgkin's Lymphoma: Comparison of Dosimetry Based on Whole-Body Retention and Dose to Critical Organ Receiving the Highest Dose.
- Published in:
- Journal of Nuclear Medicine, 2008, v. 49, n. 5, p. 837, doi. 10.2967/jnumed.107.043190
- By:
- Publication type:
- Article
From the SNM Nuclear Oncology Council.
- Published in:
- Journal of Nuclear Medicine, 2008, v. 49, n. 2, p. 30N
- By:
- Publication type:
- Article
Beyond Detection: Novel Applications for PET Imaging to Guide Cancer Therapy.
- Published in:
- Journal of Nuclear Medicine, 2007, v. 48, n. 6, p. 855, doi. 10.2967/jnumed.107.039768
- By:
- Publication type:
- Article
<sup>166</sup>Ho-DOTMP Radiation-Absorbed Dose Estimation for Skeletal Targeted Radiotherapy.
- Published in:
- Journal of Nuclear Medicine, 2006, v. 47, n. 3, p. 534
- By:
- Publication type:
- Article
High-Dose <sup>131</sup>I-Tositumomab (Anti-CD20) Radioimmunotherapy for Non-Hodgkin's Lymphoma: Adjusting Radiation Absorbed Dose to Actual Organ Volumes.
- Published in:
- Journal of Nuclear Medicine, 2004, v. 45, n. 6, p. 1059
- By:
- Publication type:
- Article
High-Dose <sup>166</sup>Ho-DOTMP in Myeloablative Treatment of Multiple Myeloma: Pharmacokinetics, Biodistribution, and Absorbed Dose Estimation.
- Published in:
- Journal of Nuclear Medicine, 2002, v. 43, n. 10, p. 1383
- By:
- Publication type:
- Article